RS54788B1 - Inhibitori pirimidina pde10 - Google Patents
Inhibitori pirimidina pde10Info
- Publication number
- RS54788B1 RS54788B1 RS20160357A RSP20160357A RS54788B1 RS 54788 B1 RS54788 B1 RS 54788B1 RS 20160357 A RS20160357 A RS 20160357A RS P20160357 A RSP20160357 A RS P20160357A RS 54788 B1 RS54788 B1 RS 54788B1
- Authority
- RS
- Serbia
- Prior art keywords
- unsubstituted
- substituted
- substituents selected
- alkyl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Jedinjenje formule I:u kome:A je izabran iz grupe koja se sastoji od:(1) piridil,(2) hinolinil,(3) naftiridinil,(4) tiazolil,(5) piridazinil,(6) oksazolil, i(7) pirazolil,(8) dihidropirolopirazolil,(9) dihidrociklopentapiridinil,(10) imidazopiridazinil, i(11) pirazolopirimidinil;B je izabran iz grupe koja se sastoji od:(1) tiazolil,(2) pirazolil,(3) tiadiazolil,(4) izoksazolil,(5) izotiazolil,(6) piridil, i(7) pirimidinil;R1a, R1b i R1c nezavisno su izabrani iz grupe koja se sastoji od:(1) vodonik,(2) halogen,(3) hidroksil,(4) -(C=O)m-On- C1-6alkil, gde m je 0 ili 1, n je 0 ili 1 (gde ako je m jednako 0 ili n je 0, prisutna je veza) i gde je alkil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(5) -(C=O)m-On-C3-6cikloalkil, gde je cikloalkil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(6) -(C=O)m-C2-4alkenil, gde je alkenil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(7) -(C=O)m-C2-4alkinil, gde je alkinil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(8) -(C=O)m-On-fenil ili -(C=O)m-On-naftil, gde je fenil ili naftil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(9) -(C=O)m-On-heteroaril, gde je heteroaril nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(10) -(C=O)m-NR10Rn,(11) -S(O)2-NR10Rn,(12) -S(O)q-R12, gde q je 0, 1 ili 2 i gde R12 je izabran od defmicija za R10 i R11,(13) -CO2H,(14) -CN, i(15) -NO2;R2a, R2b i R2c nezavisno su izabrani iz grupe koja se sastoji od:(1) vodonik,(2) halogen,(3) hidroksil,(4) -(C=O)m-On- C1-6 alkil, gde je alkil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(5) -(C=O)m-On-C3-6cikloalkil, gde je cikloalkil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(6) -(C=O)m-C2-4alkenil, gde je alkenil nesupstituisan ili supstituisan sa jednim ili višesupstituenata izabranih od R ,(7) -(C=O)m-C2-4alkinil, gde je alkinil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(8) -(C=O)m-On-fenil ili -(C=O)m-On-naftil, gde je fenil ili naftil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(9) -(C=O)m-On-heterociklil, gde je heterociklil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R13,(10) -(C=O)m-NR10R11,(11) -S(O)2-NR10R11,(12) -S(O)q-R12,(13) -CO2H,(14) -CN, i(15) -NO2;R je izabran iz grupe koja se sastoji od:(1) CH3,(2) CF3,(3) CH2F,(4) CH2CH3,(5) ciklopropil,(6) cijano,(7) vodonik,(8) NH2,(9) C(O)OR5,(10) -O-C1-6alkil,(11) -(CO)NH2,(12) C1-6alkilOH,(13) C(O)C1-6alkil,i(14) halogen;R4 je izabran iz grupe koja se sastoji od:(1) vodonik,(2) halo,(3) -C1-6alkil, i(4) cijano,R5 je izabran iz grupe koja se sastoji od:(1) vodonik, i(2) C1-6alkil;R6 je izabran iz grupe koja se sastoji od:(1) vodonik,(2) C1-6alkil, i(3) O C1-6alkil;R10 i R11 nezavisno su izabrani iz grupe koja se sastoji od:(a) vodonik,(b) C1-6alkil, koji je nesupstituisan ili supstituisan sa R14,(c) C3-6alkenil, koji je nesupstituisan ili supstituisan sa R14,(d) C3-6alkinil, koji je nesupstituisan ili supstituisan sa R14,(e) C3-6cikloalkil koji je nesupstituisan ili supstituisan sa R14,(f) C1-6alkoksil, koji je nesupstituisan ili supstituisan sa R14,(g) fenil, koji je nesupstituisan ili supstituisan sa R14, i(h) heteroaril, koji je nesupstituisan ili supstituisan sa R14,R13 je izabran iz grupe koja se sastoji od:(1) halogen,(2) hidroksil,(3) -(C=O)m-On- C1-6 alkil, gde je alkil nesupstituisan ili supstituisan sa jednim ili višesupstituenata izabranih od R14,(4) -On-(C1-3)perfluoroalkil,(5) -(C=O)m-On-C3-6cikloalkil, gde je cikloalkil nesupstituisan ili supstituisan sa jednim iliviše supstituenata izabranih od R14,(6) -(C=O)m-C2-4alkenil, gde je alkenil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R14,(7) -(C=O)m-C2-4alkinil, gde je alkinil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R14,(8) -(C=O)m-On-fenil ili -(C=O)m-On-naftil, gde je fenil ili naftil nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R14,(9) -(C=O)m-On-heteroaril, gde je heteroaril nesupstituisan ili supstituisan sa jednim ili više supstituenata izabranih od R14,(10) -(C=O)m-NR10Rn,(11) -S(O)2-NR10Rn,(12) -S(O)q-R12,(13) -CO2H,(14) -CN, i(15) -NO2;R14 je izabran iz grupe koja se sastoji od:(1) hidroksil,(2) halogen,(3) C1-6 alkil,(4) -C3-6cikloalkil,(5) -O-C1-6alkil,(6) -O(C=O)-C1-6alkil,(7) -NH- C1-6alkil,(8) fenil,(9) heteroaril,(10) -CO2H i(11) -CN;ili njegova farmaceutski prihvatljiva so.Prijava sadrži još 28 patentnih zahteva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527392P | 2011-08-25 | 2011-08-25 | |
| EP12826375.3A EP2748151B1 (en) | 2011-08-25 | 2012-08-20 | Pyrimidine pde10 inhibitors |
| PCT/US2012/051522 WO2013028590A1 (en) | 2011-08-25 | 2012-08-20 | Pyrimidine pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54788B1 true RS54788B1 (sr) | 2016-10-31 |
Family
ID=47746797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160357A RS54788B1 (sr) | 2011-08-25 | 2012-08-20 | Inhibitori pirimidina pde10 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9062059B2 (sr) |
| EP (1) | EP2748151B1 (sr) |
| JP (1) | JP5648147B2 (sr) |
| KR (1) | KR101655635B1 (sr) |
| CN (1) | CN103917528B (sr) |
| AR (1) | AR087628A1 (sr) |
| AU (1) | AU2012299080B2 (sr) |
| BR (1) | BR112014004310B8 (sr) |
| CA (1) | CA2845578C (sr) |
| CL (1) | CL2014000450A1 (sr) |
| CO (1) | CO6890101A2 (sr) |
| CR (1) | CR20140085A (sr) |
| CY (1) | CY1117622T1 (sr) |
| DK (1) | DK2748151T3 (sr) |
| DO (1) | DOP2014000039A (sr) |
| EA (1) | EA023685B1 (sr) |
| ES (1) | ES2572527T3 (sr) |
| HK (1) | HK1193410A1 (sr) |
| HR (1) | HRP20160635T1 (sr) |
| HU (1) | HUE028451T2 (sr) |
| IL (1) | IL230997A (sr) |
| MA (1) | MA35508B1 (sr) |
| ME (1) | ME02419B (sr) |
| MX (1) | MX357241B (sr) |
| MY (1) | MY157301A (sr) |
| NI (1) | NI201400014A (sr) |
| PE (1) | PE20141535A1 (sr) |
| PH (1) | PH12014500424A1 (sr) |
| PL (1) | PL2748151T3 (sr) |
| RS (1) | RS54788B1 (sr) |
| SG (1) | SG2014013536A (sr) |
| SI (1) | SI2748151T1 (sr) |
| TN (1) | TN2014000070A1 (sr) |
| TW (1) | TWI450895B (sr) |
| UA (1) | UA109735C2 (sr) |
| WO (1) | WO2013028590A1 (sr) |
| ZA (1) | ZA201401272B (sr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200001B2 (en) | 2011-10-06 | 2015-12-01 | Merck Sharp & Dohme Corp. | Triazolyl PDE10 inhibitors |
| CA2851082A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
| US9359348B2 (en) | 2012-11-15 | 2016-06-07 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine PDE10 inhibitors |
| TW201422610A (zh) | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| WO2014078216A1 (en) | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
| US9273033B2 (en) | 2012-11-20 | 2016-03-01 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as PDE10 inhibitors |
| US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
| WO2014139150A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Substituted pyridizinone derivatives as pde10 inhibitors |
| RS58509B1 (sr) | 2014-03-24 | 2019-04-30 | Novartis Ag | Organska jedinjenja monobaktama za lečenje bakterijskih infekcija |
| JP7008704B2 (ja) * | 2016-11-28 | 2022-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| JP7445610B2 (ja) | 2018-06-27 | 2024-03-07 | エフ． ホフマン－ラ ロシュ アーゲー | 医療に有用な新規化合物 |
| CA3212082A1 (en) * | 2021-03-17 | 2022-09-22 | Merck Sharp & Dohme Llc | Pro drugs of pde10 compounds |
| WO2023184486A1 (en) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Process for preparing ( (1s, 2s) -2- (5-methylpyridin-2-yl) cyclopropyl) -methanol |
| CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
| WO2024049721A1 (en) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Sustained release delivery of a pde10 inhibitor |
| WO2024099135A1 (zh) * | 2022-11-11 | 2024-05-16 | 杭州中美华东制药有限公司 | 1,5-萘啶类cGAS抑制剂及其用途 |
| WO2024206200A1 (en) * | 2023-03-29 | 2024-10-03 | Merck Sharp & Dohme Llc | Controlled release pde10a formulations |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| EP1810411A2 (en) | 2004-10-12 | 2007-07-25 | Maxlinear, Inc. | A receiver architecture with digitally generated intermediate frequency |
| KR100896380B1 (ko) | 2005-01-07 | 2009-05-08 | 화이자 프로덕츠 인코포레이티드 | 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도 |
| GB0506883D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| US20080167297A1 (en) * | 2005-04-05 | 2008-07-10 | Astrazeneca Ab | Pyrimidine Derivatives for Use as Anticancer Agents |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007129183A2 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| WO2010027097A1 (en) | 2008-09-04 | 2010-03-11 | Mitsubishi Tanabe Pharma Corporation | Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| WO2010030027A1 (en) * | 2008-09-10 | 2010-03-18 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogen-containing 6-membered ring compounds and their use |
| AR074343A1 (es) * | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
| WO2010077992A1 (en) * | 2008-12-17 | 2010-07-08 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| EP2621276B1 (en) | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
| EP2621926B1 (en) * | 2010-09-30 | 2017-08-30 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
-
2012
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/en active Application Filing
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 PH PH1/2014/500424A patent/PH12014500424A1/en unknown
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/me unknown
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/en active Active
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active IP Right Grant
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-20 CA CA2845578A patent/CA2845578C/en active Active
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
- 2014-07-07 HK HK14106824.3A patent/HK1193410A1/zh unknown
-
2016
- 2016-06-08 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54788B1 (sr) | Inhibitori pirimidina pde10 | |
| RS51471B (sr) | Derivati bifeniloksisirćetne kiseline za tretman bolesti dišnog trakta | |
| RS54506B1 (sr) | Derivati pikolinamida kao inhibitori kinaza | |
| MY187479A (en) | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | |
| EA201791815A1 (ru) | Конденсированные гетероциклические соединения и пестициды | |
| AR101586A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| MY186898A (en) | Condensed heterocyclic compounds and pesticides | |
| EP4272824A3 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| RS54848B1 (sr) | Nova pesticidna jedinjenja na bazi pirazola | |
| RS54202B1 (sr) | Hinolin i hinoksalin derivati kao inhibitori kinaza | |
| PH12013501873A1 (en) | Novel imidazo-oxazine compound or salt thereof | |
| RS54708B1 (sr) | Ariletinil derivati | |
| RS53928B1 (sr) | Herbicidna jedinjenja | |
| RS53156B (sr) | N1-pirazolospiroketoni kao inhibitori acetil-coa karboksilaze | |
| RS54183B1 (sr) | Derivati pirazola | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| WO2018065311A8 (en) | Herbicidal mixtures | |
| JO3509B1 (ar) | معدلات p2x7 | |
| UA116794C2 (uk) | Моноциклічна піридинова похідна | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| WO2009095792A3 (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
| DK2868660T3 (da) | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse | |
| MX2018005133A (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
| NZ602883A (en) | Novel synthesis for thiazolidinedione compounds |